ADT Linked to Increased Dementia Risk in Prostate Cancer Patients
Androgen deprivation therapy (ADT), a mainstay of treatment for men with prostate cancer, may raise the risk of dementia, according to a new study.
First-Line Vaccine Did Not Improve Survival in Metastatic RCC
The addition of the IMA901 vaccine to sunitinib for the first-line treatment of metastatic renal cell carcinoma did not improve overall survival.
Cabozantinib Shows Potential for First-Line RCC
Treatment with cabozantinib resulted in significantly improved PFS and overall response vs sunitinib for patients with metastatic renal cell carcinoma.
Sunitinib Potential New Option for Adjuvant Treatment in RCC
Patients with renal cell carcinoma at high risk for recurrence had prolonged disease-free survival when treated with sunitinib compared with placebo.
Enzalutamide Shows Efficacy in Prostate Cancer With Visceral Mets
Patients with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases (liver and lung) fare better with the androgen receptor inhibitor enzalutamide than placebo, according to a new analysis from the phase III AFFIRM trial.
FDA Announces Nivolumab Dose Change for RCC, NSCLC, Metastatic Melanoma
The FDA announced a modification to the recommended dosage regimen for nivolumab (Opdivo) for renal cell carcinoma (RCC), metastatic melanoma, and non–small-cell lung cancer (NSCLC).
Vasectomy Not Linked to Increased Risk of Prostate Cancer
Men who have vasectomies do not have a higher risk of prostate cancer and are not more likely to die from the disease, according to a large, prospective study.
Continuing Nivolumab After Progression Improves Survival in RCC
In this video we discuss the continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial.
Considering Neoadjuvant Chemotherapy Options in Bladder Cancer
In this peer-to-peer discussion Dr. Grivas and Dr. Palmbos examine the role of neoadjuvant chemotherapy in bladder cancer and weigh the various trial data guiding these treatment decisions.
First-Line Atezolizumab Effective in Cisplatin-Ineligible Urothelial Cancer
Results of the IMvigor210 clinical trial found that atezolizumab is effective in patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma.
Adjuvant Chemo Ups Survival in High-Risk Localized Prostate Cancer
The addition of docetaxel and prednisone to standard therapy may be the first effective adjuvant chemotherapy treatment for high-risk prostate cancer patients.
Oncology Drug Snapshot: Axitinib (Inlyta)
This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Slide Show: Genitourinary Cancers
This slide show features pathology images of bladder cancer, prostate cancer, renal cell carcinoma, and testicular cancer.
By clicking Accept, you agree to become a member of the UBM Medica Community.